Acutus Medical, Inc. (AFIB)
USD 0.03
(6.67%)
USD 0.03
(6.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -81.66 Million USD | -106.14% |
| 2022 | -39.61 Million USD | 67.89% |
| 2021 | -123.36 Million USD | -20.96% |
| 2020 | -101.98 Million USD | 14.52% |
| 2019 | -119.3 Million USD | -149.04% |
| 2018 | -47.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -914 Thousand USD | 43.58% |
| 2024 Q1 | -1.62 Million USD | 95.2% |
| 2023 Q1 | -16.63 Million USD | -210.07% |
| 2023 FY | -81.66 Million USD | -106.14% |
| 2023 Q3 | -13.23 Million USD | 27.85% |
| 2023 Q2 | -18.34 Million USD | -10.32% |
| 2023 Q4 | -33.76 Million USD | -155.08% |
| 2022 Q3 | -20.38 Million USD | -483.88% |
| 2022 Q2 | -3.49 Million USD | 91.57% |
| 2022 Q1 | -41.4 Million USD | -32.43% |
| 2022 FY | -39.61 Million USD | 67.89% |
| 2022 Q4 | 15.1 Million USD | 174.1% |
| 2021 FY | -123.36 Million USD | -20.96% |
| 2021 Q3 | -28.51 Million USD | 0.75% |
| 2021 Q4 | -31.26 Million USD | -9.66% |
| 2021 Q2 | -28.72 Million USD | 1.56% |
| 2021 Q1 | -29.18 Million USD | 0.75% |
| 2020 Q3 | -31.28 Million USD | -34.9% |
| 2020 Q2 | -23.19 Million USD | -28.15% |
| 2020 Q1 | -18.09 Million USD | 9.12% |
| 2020 FY | -101.98 Million USD | 14.52% |
| 2020 Q4 | -29.4 Million USD | 6.03% |
| 2019 Q1 | -14.69 Million USD | 0.0% |
| 2019 FY | -119.3 Million USD | -149.04% |
| 2019 Q4 | -19.91 Million USD | 37.93% |
| 2019 Q3 | -32.08 Million USD | -5.73% |
| 2019 Q2 | -30.34 Million USD | -106.5% |
| 2018 FY | -47.9 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Biotricity, Inc. | -14.09 Million USD | -479.405% |
| Cell MedX Corp. | -142.48 Thousand USD | -57212.999% |
| Dynatronics Corporation | -2.69 Million USD | -2927.113% |
| Nemaura Medical Inc. | -14.14 Million USD | -477.379% |
| PetVivo Holdings, Inc. | -10.95 Million USD | -645.42% |
| RetinalGenix Technologies Inc. | -2.09 Million USD | -3805.659% |
| Sonendo, Inc. | -60.91 Million USD | -34.052% |
| Telesis Bio, Inc. | -47.72 Million USD | -71.115% |
| Talis Biomedical Corporation | -62 Million USD | -31.7% |
| Viveve Medical, Inc. | -22.02 Million USD | -270.74% |